Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia
To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with...
Gespeichert in:
| Veröffentlicht in: | Therapeutic drug monitoring 1991, Vol.13 (1), p.37-41 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 41 |
|---|---|
| container_issue | 1 |
| container_start_page | 37 |
| container_title | Therapeutic drug monitoring |
| container_volume | 13 |
| creator | ZUCCARO, P GUANDALINI, S PACIFICI, R PICHINI, S DI MARTINO, L GUIDUCCI, M GIULIANO, M DI TULLIO, M. T MANTOVANI, M. P |
| description | To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests. No correlation was found between estimates of small intestinal absorption (the oral lactose tolerance test and 1 h blood xylose test) and 6-mercaptopurine serum levels. Of the anthropometric measurements considered, only the weight/height percentile (an index of the fat body mass) strongly and linearly correlated with the area under the curve of 6-mercaptopurine. The dose of 75 mg of 6-mercaptopurine/m2 of body surface resulted in higher serum concentrations in children below the 75th percentile than in those with a weight/height ratio exceeding the 75th percentile. In conclusion, these data caution about the risk of underdosing 6-mercaptopurine in overweight children when administering it on the basis of body surface area. |
| doi_str_mv | 10.1097/00007691-199101000-00004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80645053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80645053</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-e9183177372507927d29a2c817c8e59248f3ec04efd042ffcd128fb90b5fb7a63</originalsourceid><addsrcrecordid>eNpFUMtO3TAQtapWcKH9BCRvYJd2_IgfywpBWwmJTbuOJo6t6-LEqZ0I3b8nwIXOZjTnNdIhhDL4ysDqb7CNVpY1zFoGbLuaZ0h-IDvWCtUIZeVHsgOmRCNFq07JWa1_AZg0ACfkhEOrrbE7Em9xoX0eDnTEWilOA533WEZ0-SFOfomu0hxoLpioakZfHM5LnteykTRO1O1jGoqf6GNc9hTduniaDuO8z33Cutlp8uuDHyN-Jp8Cpuq_HPc5-XN78_v6Z3N3_-PX9fe7xgkJS-MtM4JpLTRvQVuuB26RO8O0M761XJogvAPpwwCSh-AGxk3oLfRt6DUqcU6uXnPnkv-tvi7dGKvzKeHk81o7A0q20IpNaF6FruRaiw_dXOKI5dAx6J5b7t5a7t5bfoHkZr04_lj70Q_vxmOtG3955LE6TKHg5GL9n2-VZsZw8QSAAIWP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80645053</pqid></control><display><type>article</type><title>Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>ZUCCARO, P ; GUANDALINI, S ; PACIFICI, R ; PICHINI, S ; DI MARTINO, L ; GUIDUCCI, M ; GIULIANO, M ; DI TULLIO, M. T ; MANTOVANI, M. P</creator><creatorcontrib>ZUCCARO, P ; GUANDALINI, S ; PACIFICI, R ; PICHINI, S ; DI MARTINO, L ; GUIDUCCI, M ; GIULIANO, M ; DI TULLIO, M. T ; MANTOVANI, M. P</creatorcontrib><description>To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests. No correlation was found between estimates of small intestinal absorption (the oral lactose tolerance test and 1 h blood xylose test) and 6-mercaptopurine serum levels. Of the anthropometric measurements considered, only the weight/height percentile (an index of the fat body mass) strongly and linearly correlated with the area under the curve of 6-mercaptopurine. The dose of 75 mg of 6-mercaptopurine/m2 of body surface resulted in higher serum concentrations in children below the 75th percentile than in those with a weight/height ratio exceeding the 75th percentile. In conclusion, these data caution about the risk of underdosing 6-mercaptopurine in overweight children when administering it on the basis of body surface area.</description><identifier>ISSN: 0163-4356</identifier><identifier>EISSN: 1536-3694</identifier><identifier>DOI: 10.1097/00007691-199101000-00004</identifier><identifier>PMID: 2057989</identifier><identifier>CODEN: TDMODV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Administration, Oral ; Adolescent ; Antineoplastic agents ; Biological and medical sciences ; Biological Availability ; Body Weight ; Child ; Child, Preschool ; Female ; General aspects ; Humans ; Intestinal Absorption - drug effects ; Male ; Medical sciences ; Mercaptopurine - administration & dosage ; Mercaptopurine - pharmacokinetics ; Mercaptopurine - therapeutic use ; Pharmacology. Drug treatments ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</subject><ispartof>Therapeutic drug monitoring, 1991, Vol.13 (1), p.37-41</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-e9183177372507927d29a2c817c8e59248f3ec04efd042ffcd128fb90b5fb7a63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19671882$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2057989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ZUCCARO, P</creatorcontrib><creatorcontrib>GUANDALINI, S</creatorcontrib><creatorcontrib>PACIFICI, R</creatorcontrib><creatorcontrib>PICHINI, S</creatorcontrib><creatorcontrib>DI MARTINO, L</creatorcontrib><creatorcontrib>GUIDUCCI, M</creatorcontrib><creatorcontrib>GIULIANO, M</creatorcontrib><creatorcontrib>DI TULLIO, M. T</creatorcontrib><creatorcontrib>MANTOVANI, M. P</creatorcontrib><title>Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia</title><title>Therapeutic drug monitoring</title><addtitle>Ther Drug Monit</addtitle><description>To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests. No correlation was found between estimates of small intestinal absorption (the oral lactose tolerance test and 1 h blood xylose test) and 6-mercaptopurine serum levels. Of the anthropometric measurements considered, only the weight/height percentile (an index of the fat body mass) strongly and linearly correlated with the area under the curve of 6-mercaptopurine. The dose of 75 mg of 6-mercaptopurine/m2 of body surface resulted in higher serum concentrations in children below the 75th percentile than in those with a weight/height ratio exceeding the 75th percentile. In conclusion, these data caution about the risk of underdosing 6-mercaptopurine in overweight children when administering it on the basis of body surface area.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Body Weight</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Intestinal Absorption - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mercaptopurine - administration & dosage</subject><subject>Mercaptopurine - pharmacokinetics</subject><subject>Mercaptopurine - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</subject><issn>0163-4356</issn><issn>1536-3694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFUMtO3TAQtapWcKH9BCRvYJd2_IgfywpBWwmJTbuOJo6t6-LEqZ0I3b8nwIXOZjTnNdIhhDL4ysDqb7CNVpY1zFoGbLuaZ0h-IDvWCtUIZeVHsgOmRCNFq07JWa1_AZg0ACfkhEOrrbE7Em9xoX0eDnTEWilOA533WEZ0-SFOfomu0hxoLpioakZfHM5LnteykTRO1O1jGoqf6GNc9hTduniaDuO8z33Cutlp8uuDHyN-Jp8Cpuq_HPc5-XN78_v6Z3N3_-PX9fe7xgkJS-MtM4JpLTRvQVuuB26RO8O0M761XJogvAPpwwCSh-AGxk3oLfRt6DUqcU6uXnPnkv-tvi7dGKvzKeHk81o7A0q20IpNaF6FruRaiw_dXOKI5dAx6J5b7t5a7t5bfoHkZr04_lj70Q_vxmOtG3955LE6TKHg5GL9n2-VZsZw8QSAAIWP</recordid><startdate>1991</startdate><enddate>1991</enddate><creator>ZUCCARO, P</creator><creator>GUANDALINI, S</creator><creator>PACIFICI, R</creator><creator>PICHINI, S</creator><creator>DI MARTINO, L</creator><creator>GUIDUCCI, M</creator><creator>GIULIANO, M</creator><creator>DI TULLIO, M. T</creator><creator>MANTOVANI, M. P</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1991</creationdate><title>Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia</title><author>ZUCCARO, P ; GUANDALINI, S ; PACIFICI, R ; PICHINI, S ; DI MARTINO, L ; GUIDUCCI, M ; GIULIANO, M ; DI TULLIO, M. T ; MANTOVANI, M. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-e9183177372507927d29a2c817c8e59248f3ec04efd042ffcd128fb90b5fb7a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Body Weight</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Intestinal Absorption - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mercaptopurine - administration & dosage</topic><topic>Mercaptopurine - pharmacokinetics</topic><topic>Mercaptopurine - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ZUCCARO, P</creatorcontrib><creatorcontrib>GUANDALINI, S</creatorcontrib><creatorcontrib>PACIFICI, R</creatorcontrib><creatorcontrib>PICHINI, S</creatorcontrib><creatorcontrib>DI MARTINO, L</creatorcontrib><creatorcontrib>GUIDUCCI, M</creatorcontrib><creatorcontrib>GIULIANO, M</creatorcontrib><creatorcontrib>DI TULLIO, M. T</creatorcontrib><creatorcontrib>MANTOVANI, M. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic drug monitoring</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ZUCCARO, P</au><au>GUANDALINI, S</au><au>PACIFICI, R</au><au>PICHINI, S</au><au>DI MARTINO, L</au><au>GUIDUCCI, M</au><au>GIULIANO, M</au><au>DI TULLIO, M. T</au><au>MANTOVANI, M. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia</atitle><jtitle>Therapeutic drug monitoring</jtitle><addtitle>Ther Drug Monit</addtitle><date>1991</date><risdate>1991</risdate><volume>13</volume><issue>1</issue><spage>37</spage><epage>41</epage><pages>37-41</pages><issn>0163-4356</issn><eissn>1536-3694</eissn><coden>TDMODV</coden><abstract>To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests. No correlation was found between estimates of small intestinal absorption (the oral lactose tolerance test and 1 h blood xylose test) and 6-mercaptopurine serum levels. Of the anthropometric measurements considered, only the weight/height percentile (an index of the fat body mass) strongly and linearly correlated with the area under the curve of 6-mercaptopurine. The dose of 75 mg of 6-mercaptopurine/m2 of body surface resulted in higher serum concentrations in children below the 75th percentile than in those with a weight/height ratio exceeding the 75th percentile. In conclusion, these data caution about the risk of underdosing 6-mercaptopurine in overweight children when administering it on the basis of body surface area.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>2057989</pmid><doi>10.1097/00007691-199101000-00004</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-4356 |
| ispartof | Therapeutic drug monitoring, 1991, Vol.13 (1), p.37-41 |
| issn | 0163-4356 1536-3694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80645053 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Administration, Oral Adolescent Antineoplastic agents Biological and medical sciences Biological Availability Body Weight Child Child, Preschool Female General aspects Humans Intestinal Absorption - drug effects Male Medical sciences Mercaptopurine - administration & dosage Mercaptopurine - pharmacokinetics Mercaptopurine - therapeutic use Pharmacology. Drug treatments Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism |
| title | Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A38%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fat%20body%20mass%20and%20pharmacokinetics%20of%20oral%206-mercaptopurine%20in%20children%20with%20acute%20lymphoblastic%20leukemia&rft.jtitle=Therapeutic%20drug%20monitoring&rft.au=ZUCCARO,%20P&rft.date=1991&rft.volume=13&rft.issue=1&rft.spage=37&rft.epage=41&rft.pages=37-41&rft.issn=0163-4356&rft.eissn=1536-3694&rft.coden=TDMODV&rft_id=info:doi/10.1097/00007691-199101000-00004&rft_dat=%3Cproquest_cross%3E80645053%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80645053&rft_id=info:pmid/2057989&rfr_iscdi=true |